Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Porter

Showing results (671-680 of 764) with videos related to

Pageof 77
Sort By:
Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivativesP C Astles, C Brealey, T J Brown, et al.
Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivativesP C Astles, T J Brown, F Halley, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 19, 1999
An analysis of the effect of age on survival after heart transplantA M Borkon, G F Muehlebach, P G Jones, et al.
Blood|January 4, 2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Dudley J Pennell, John B Porter, Antonio Piga, et al.
Blood Advances|February 8, 2024
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J van Beers, Hanny Al-Samkari, Rachael F Grace, et al.
Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Mayo Clinic Proceedings|March 16, 2020
An Institutional Approach to Managing the Opioid CrisisHalena M Gazelka, Casey M Clements, Julie L Cunningham, et al.
Journal of Neuro-Oncology|May 3, 2022
Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI)Krissia M Rivera Perla, Oliver Y Tang, Shayla N M Durfey, et al.
Pediatric Hematology and Oncology|August 3, 2010
Transfusion and chelation practices in sickle cell disease: a regional perspectiveElliott P Vichinsky, Kwaku Ohene-Frempong, Swee Lay Thein, et al.
Pageof 77

Showing results (671-680 of 764) with videos related to

Sort By:
Pageof 77
Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivativesP C Astles, C Brealey, T J Brown, et al.
Journal of Medicinal Chemistry|July 21, 1998
Selective endothelin A receptor antagonists. 4. Discovery and structure-activity relationships of stilbene acid and alcohol derivativesP C Astles, T J Brown, F Halley, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|August 19, 1999
An analysis of the effect of age on survival after heart transplantA M Borkon, G F Muehlebach, P G Jones, et al.
Blood|January 4, 2014
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)Dudley J Pennell, John B Porter, Antonio Piga, et al.
Blood Advances|February 8, 2024
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J van Beers, Hanny Al-Samkari, Rachael F Grace, et al.
Transfusion|June 3, 2008
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusionsEllen B Fung, Paul R Harmatz, Meredith Milet, et al.
British Journal of Haematology|October 27, 2025
Achieving clinically meaningful changes in haemoglobin levels in patients with non-transfusion-dependent β-thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trialKhaled M Musallam, Ali T Taher, John B Porter, et al.
Mayo Clinic Proceedings|March 16, 2020
An Institutional Approach to Managing the Opioid CrisisHalena M Gazelka, Casey M Clements, Julie L Cunningham, et al.
Journal of Neuro-Oncology|May 3, 2022
Predicting access to postoperative treatment after glioblastoma resection: an analysis of neighborhood-level disadvantage using the Area Deprivation Index (ADI)Krissia M Rivera Perla, Oliver Y Tang, Shayla N M Durfey, et al.
Pediatric Hematology and Oncology|August 3, 2010
Transfusion and chelation practices in sickle cell disease: a regional perspectiveElliott P Vichinsky, Kwaku Ohene-Frempong, Swee Lay Thein, et al.
Pageof 77